Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
SIENTRA Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
UNITEDHEALTH | 264,95 | +0,36 % | United-Health-Konkurrent: Kaufchance? Diese Aktie ist einfach viel zu billig! | © Foto: Google GeminiDie Aktie des US-Krankenversicherers Centene ist so günstig wie lange nicht. Das gilt nicht nur für die Aktie, sondern auch die Bewertung des Unternehmens.In der US-Krankenversicherungsbranche... ► Artikel lesen | |
TELADOC HEALTH | 7,332 | +2,12 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
THERMO FISHER | 342,55 | -1,78 % | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply | Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration... ► Artikel lesen | |
ROKU | 74,75 | +0,66 % | Should You Buy Roku Stock After Its Partnership With Amazon? | ||
RESMED | 217,80 | -0,05 % | ResMed-Aktie: Kurs steigt nur geringfügig (220,1782 €) | An der US-amerikanischen Börse ist die Aktie von ResMed zur Stunde unauffällig. Der jüngste Kurs betrug 254,22 US-Dollar. Kaum verändert im Vergleich zu der Schlussnotierung vom Vortag zeigt sich aktuell... ► Artikel lesen | |
HENRY SCHEIN | 62,12 | -0,74 % | Is Henry Schein Stock Outperforming the Dow? | ||
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
ZIMMER BIOMET | 77,78 | -1,52 % | Dividendenbekanntmachungen (26.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AUDIUS SE DE000A40ET13 - 0,2 EUR B&M EUROPEAN VALUE RETAIL SA LU1072616219 0,097 GBP 0,1136 EUR BUILD-A-BEAR WORKSHOP INC US1200761047 0... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
PETMED EXPRESS | 2,800 | -0,99 % | Petmed Express Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
TANDEM DIABETES | 16,165 | 0,00 % | TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 + | ||
VERU | 0,506 | -1,94 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
QUIDELORTHO | 24,600 | -0,81 % | QuidelOrtho Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen |